 Thanks. Thanks very much. Before I get started with the introduction to the next section, I talked with Bill over the break, and I think Bill wants to give a bit of perspective from the point of view of the scientific advisors to the Genome Sequencing Program. Thank you, Adam. So for those of you who don't know me, I'm Bill Gelbart. Since its inception, I've been on the sequencing advisory panel, and when Rick Lyfton decided to become a grantee, I was asked to chair the panel. And I just want to make a few comments. One is that since its inception, the NHGRI has viewed the Sequencing Program as a portfolio. That portfolio was fairly simple at the beginning, really focused on getting human genome out and a few other comparative genomes. But in its last iteration, it obviously became much more complex with, in addition to large scale centers, the CMGs, the CSER and ROR programs, and the genome informatics program, tools development program. And I just want to say that there's potential because we're going to talk about different aspects of the program separately, that we can still think of these as totally separate components. But as someone said yesterday, these have been siloed, and I think that's a fair comment, to a large degree in the current iteration of the program. And we really need to think about whether that's the right model or whether we really want to see much more crosstalk and much more deep collaboration between the different elements of the program moving forward. And so I hope we have a chance to consider that today. And the other is that just to remind you of something you all know is that the technology development and genome sequencing, genome assembly, and analysis really has been led by this program internationally. And I just want to emphasize that this is still incredibly important. And however we develop the scenarios, I sincerely hope that that does not fall out of this program, but is a core component of it. That's all I have to say.